Satellos Bioscience Inc ICOTF

Primary Symbol: T.MSCL Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based a drug discovery and development company with a focus on muscle regeneration. The Company is focused on developing medicines to treat degenerative muscle conditions. Its MyoReGenX platform is specifically designed to recreate the specialized muscle stem cell niche in vitro. MyoReGenX platform enables to map pathways which modulate muscle repair and regeneration, identify, and confirm drug targets, and test drug candidates for their ability to restore muscle stem cell repair mechanisms that have been impaired by genetic mutations, disease or injury. Its lead program is an oral, small molecule drug candidate in development as a disease-modifying treatment for Duchenne muscular dystrophy. Its iCo portfolio includes Oral Amp B Delivery System, a patented oral transport technology and Bertilimumab a human monoclonal eotaxin antibody with potential to treat a range of allergic and inflammatory conditions mediated by eotaxin-1.

TSX:MSCL - Post by User

Satellos Bioscience Inc

Bullboard Posts

Comment by TSX-Newson Aug 21, 2014 1:41am

199 Views

Post# 22863394

RE:RE:IMNP was $100 in 2009

That doesn't change the chart nor the ability to reach $100. IMNP has a $64M market cap at $4, plenty of biotech stocks in the 100's of millions or a billion with Ph2 or Ph3 drugs. All it needs is someone to fall in love with the story down south once it trades on a real exchange.

Bullboard Posts

5 steps to mastering risk management in the stock market